Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New brain scan method aims to spot Alzheimer's and Parkinson's early

NCT ID NCT06080659

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing whether a new, low-cost type of brain scan can find early signs of Alzheimer's and Parkinson's disease. Researchers will compare brain scans from 120 people, including those at risk for Alzheimer's, those with Parkinson's, and healthy volunteers. The goal is to see if these scans can serve as a simple, non-invasive biomarker for early diagnosis.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 120 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2023

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

50 to 80 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * For all participants: * French mother tongue * right-handed * with a level of education equal to or higher than the Certificat d'Études Primaires (Primary School Certificate) * Free of any medical or psychiatric condition likely to interfere with cognition (excluding diagnosis for patients) * Affiliated with a social security scheme * Having received oral and written information about the protocol and having signed a consent form to participate in this research. DCS+ group: \- Meeting the diagnostic criteria for "subjective cognitive decline-plus" (Jessen criteria (Jessen et al., 2014). Alzheimer's patients "Mild Cognitive Impairment due to Alzheimer's Disease," "MCI-MA": \- Meeting the diagnostic criteria for "Mild neurocognitive disorder due to Alzheimer's disease" (criteria of (Albert et al., 2011)) De novo" Parkinsonian patients, "MPdn": \- Presenting with newly diagnosed ("de novo") Parkinson's disease and free of cognitive deficits (criteria of Postuma et al., 2015 (Postuma et al., 2015)) Parkinsonian patients with "Mild Cognitive Impairment, "MCI-MP": \- Presenting Parkinson's disease associated with "mild neurocognitive impairment" (criteria of Litvan et al., 2012 (Litvan et al., 2012)) Exclusion Criteria: * All participants (healthy volunteers and patients) * Contraindications to MRI : * Abdominal circumference + upper limbs sticking to the body \> 200 cm; * Implantable pacemaker or defibrillator; * Neurosurgical clips; * Cochlear implants ; * Neural or peripheral stimulator; * Intra-orbital or encephalic metallic foreign bodies; * Endoprostheses fitted less than 4 weeks ago and osteosynthesis devices fitted less than 6 weeks ago; * Claustrophobia. * Pregnant or breast-feeding women; * Adults under legal protection (safeguard of justice, curatorship, guardianship), persons deprived of liberty. Patients only * Score \>2 on the modified Hachinski scale (Hachinski et al., 2012) * Dementia according to McKhann criteria (McKhann et al., 2011) * Sensory deficit interfering with experimental tests Healthy volunteers only \- Cognitive impairment (MoCA score \< 26)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Alzheimer disease, early onset are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • CHU Rennes

    RECRUITING

    Rennes, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.